News & Trends - Pharmaceuticals

Arthritis drugs reduce mortality of critically ill COVID-19 patients

Health Industry Hub | March 3, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Two arthritis treatments have been found to have a significant impact on the survival rate of critically ill COVID-19 patients, with mortality reduced by 8.5%.

These immunosuppressive drugs, Roche’s Actemra (tocilizumab) and Sanofi’s Kevzara (sarilumab), were also found to improve recovery times, with the average tocilizumab and sarilumab patients discharged from the intensive care unit (ICU) a week earlier.

The findings come from the REMAP-CAP trial, led in Australia by researchers at the Australian and New Zealand Intensive Care Research Centre, located within Monash University’s School of Public Health and Preventive Medicine. The trial evaluates the effect of numerous treatment options for critically ill COVID patients, and is supported by Minderoo Foundation. The new findings were published in the New England Journal of Medicine.

Interview links will be provided next week.

The successful results of tocilizumab and sarilumab occurred in patients also receiving corticosteroid therapy, meaning the benefit of these arthritis drugs adds to the positive outcomes from corticosteroid therapy, the only other effective treatment identified for critically ill COVID-19 patients.

Initial findings reported by the researchers in November showed that tocilizumab, was likely to improve outcomes among critically ill COVID-19 patients, but the impact on patient survival and length of time on organ support in ICU was not clear at that time.

Professor Steve Webb from the trial said this is a significant finding which will have immediate implications for the sickest patients with COVID-19.

“We found that among critically ill adult patients – those receiving breathing support in intensive care – treatment with these drugs can improve their chance of survival and recovery,” Professor Webb said.

In May 2020, Minderoo Foundation provided $2 million funding to expand the COVID-19 domains of the REMAP-CAP trial, providing critically ill patients access to the study’s novel treatments. This funding also included facilitated the expansion of the study into low socio-economic areas including Pakistan, Nepal and India.

Dr Steve Burnell who leads Minderoo Foundation’s COVID-19 response said Minderoo is incredibly proud to be supporting REMAP-CAP.

“REMAP-CAP’s agility and flexibility are what make it so innovative, its design enables researchers and physicians to collaborate, test treatments and share results quickly.

“Australia is fortunate to have had relatively few COVID-19 cases, but the pandemic continues to have a devastating impact in many countries. These latest results will ensure more critically ill patients around the world receive the life-saving treatments they need”, Dr Burnell said.

At the end of last year, positive early findings on tocilizumab were released before the full data had been collected. With the full analysis now available, researchers are confident the findings will have immediate clinical implications for patients, particularly as similar results have been reported subsequently from the RECOVERY trial.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]